The removal of a large KKR overhang is a modest positive for the stock, but the secondary itself is a neutral event for BridgeBio's fundamentals. Monitor for any subsequent insider selling or changes in institutional ownership post-offering.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $79.89entry
- T+1 · 3mo ago +3.87%α +4.54% · $82.98
- T+5 · 3mo ago +1.48%α +2.67% · $81.07
- T+20 · 2mo ago −9.40%α −7.87% · $72.38
- T+60 · 6d ago −2.45%α +0.31% · $77.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock at $78.00 per share in an underwritten secondary offering. BridgeBio receives no proceeds, but the transaction diversifies its shareholder base and removes a large overhang from a major institutional holder. The offering is expected to close on August 17, 2026, with a 30-day lock-up on the selling stockholder.
Key Facts
- KKR Genetic Disorder L.P. is selling 5,000,000 shares of BBIO common stock at $78.00 per share.
- BridgeBio will not receive any proceeds from the offering.
- The offering is oversubscribed and priced at $78.00 per share, with underwriters paying $77.415 per share.
- Underwriters include William Blair, Goldman Sachs, and KKR Capital Markets.
- The selling stockholder is subject to a 30-day lock-up agreement.
- The offering is expected to close on August 17, 2026.
Financial Impact
Secondary offering of 5,000,000 shares at $78.00 per share; gross proceeds of $390 million to the selling stockholder. BridgeBio receives $0.
Risk Factors
- No direct financial benefit to BridgeBio from the offering.
- Potential for further selling by other large holders if the lock-up expiration leads to distribution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-033282 |
| Document: ef20080234_8k.htm | 0001140361-26-033282 |
| Document: ef20080234_ex99-2.htm | 0001140361-26-033282 |
| Document: ef20080234_ex5-1.htm | 0001140361-26-033282 |
| Document: ef20080234_ex99-1.htm | 0001140361-26-033282 |
| Document: 0001140361-26-033282-index-headers.html | 0001140361-26-033282 |
| Document: 0001140361-26-033282-index.html | 0001140361-26-033282 |
| Document: 0001140361-26-033282.txt | 0001140361-26-033282 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers